Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 2.400-2.500 for the period, compared to the consensus earnings per share estimate of 2.450. The company issued revenue guidance of $16.1 billion-$16.5 billion, compared to the consensus revenue estimate of $16.3 billion. Teva Pharmaceutical Industries also updated its FY24 guidance to $2.40-2.50 EPS.
Analyst Upgrades and Downgrades
A number of brokerages have commented on TEVA. Argus raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and set a $20.00 target price for the company in a report on Wednesday, July 10th. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an "overweight" rating in a research report on Wednesday, October 23rd. UBS Group boosted their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. Finally, JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, October 21st. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of "Moderate Buy" and a consensus price target of $19.67.
Read Our Latest Report on TEVA
Teva Pharmaceutical Industries Trading Down 7.1 %
Shares of NYSE TEVA traded down $1.34 on Wednesday, hitting $17.43. The company's stock had a trading volume of 13,694,810 shares, compared to its average volume of 9,275,844. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. Teva Pharmaceutical Industries has a 12-month low of $8.55 and a 12-month high of $19.31. The stock has a 50 day moving average of $18.03 and a 200-day moving average of $17.06.
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Recommended Stories
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
